Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIORELLO finerenone long-term safety extension in pediatric heart failure with LV systolic dysfunction
2024-519830-22-00Phase 3Authorised
- Sponsor
- Bayer
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, open-label, single-arm trial of finerenone in heart failure (HF) and left ventricular systolic dysfunction (LVSD), sponsored by Bayer. Primary endpoints: Treatment-emergent adverse events, Change in serum potassium and 2 more. Planned start Apr 2026; status: authorised.
02
Drugs
finerenone
03
Conditions
heart failure (HF)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on 2024-519830-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519830-22-00.